Fig. 3: Kaplan–Meier estimates of the duration of response, progression-free survival, and overall survival.

A Shows the duration of response of the 66 patients who had a response, including the patients with aggressive disease (including DLBCL, tFL and PMBCL) or FL. B Shows progression-free survival for all 87 patients who received an infusion, including the patients with aggressive disease (including DLBCL, tFL and PMBCL) or FL. The progression-free survival time was recorded as the date of TanCAR7 T cell infusion to the date of disease progression or death from any cause. Subjects not meeting the criteria for progression by the data analysis cut-off date were censored at their last evaluable disease assessment date. Data from 4 other patients were censored: 3 received interventional treatment, and 1 was lost to follow-up. C Shows the overall survival for all 87 patients who received an infusion or patients with aggressive disease (including DLBCL, tFL and PMBCL) or FL. The overall survival time was recorded as the date of TanCAR7 T cell infusion to the date of death from any cause. Patients who did not have an event had their data censored for the analyses at the date at which they were last known to be alive. DLBCL diffuse large B-cell lymphoma, FL follicular lymphoma, PMBCL primary mediastinal B-cell lymphoma, tFL transformed follicular lymphoma.